Champions Oncology Inc (CSBR) CEO Joel Ackerman Acquires 8,202 Shares
Champions Oncology Inc (OTCMKTS:CSBR) CEO Joel Ackerman purchased 8,202 shares of the firm’s stock in a transaction that occurred on Friday, October 7th. The shares were bought at an average price of $1.63 per share, with a total value of $13,369.26. Following the completion of the acquisition, the chief executive officer now owns 1,027,764 shares of the company’s stock, valued at approximately $1,675,255.32. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Joel Ackerman also recently made the following trade(s):
- On Friday, September 23rd, Joel Ackerman purchased 33 shares of Champions Oncology stock. The shares were bought at an average price of $1.65 per share, with a total value of $54.45.
- On Wednesday, September 21st, Joel Ackerman purchased 5,000 shares of Champions Oncology stock. The shares were bought at an average price of $1.66 per share, with a total value of $8,300.00.
Shares of Champions Oncology Inc (OTCMKTS:CSBR) traded up 0.61% during trading on Friday, reaching $1.65. 12,710 shares of the company traded hands. Champions Oncology Inc has a 12 month low of $1.11 and a 12 month high of $5.49. The stock’s 50 day moving average price is $1.69 and its 200-day moving average price is $2.64. The stock’s market cap is $18.10 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/champions-oncology-inc-csbr-ceo-joel-ackerman-acquires-8202-shares.html
Champions Oncology (OTCMKTS:CSBR) last issued its quarterly earnings data on Friday, September 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. The company earned $3.70 million during the quarter.
About Champions Oncology
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.